Could High-Dose testosterone boost chemo against Hard-to-Treat prostate cancer?

NCT ID NCT06039371

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether giving high levels of testosterone alongside chemotherapy (carboplatin or etoposide) or a targeted radioactive drug (LuPSMA) can shrink tumors in men with advanced prostate cancer that has stopped responding to hormone therapy. The study will enroll 69 participants and measure how many have a significant drop in PSA levels. The goal is to find a new way to treat this aggressive form of prostate cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: testosterone, carboplatin, etoposide, lutetium Lu-177 PSMA-617
What this could lead to: If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a small, early-phase trial (69 people) and the combination may cause significant side effects. It is not yet known if it will improve survival or quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE ADENOCARCINOMA STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.